Latest News for PAVM
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
PAVmed Inc. (PAVM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $2.1 per share a year ago.
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened its balance sheet ahead of key upcoming reimbursement milestones PAVmed advanced its relaunched medical device portfolio; evaluation of additional acquisition opportunities ongoing Conference call and webcast to be held…
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May 14, at 8:30 AM EDT NEW YORK, May 14, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PAVM.
U.S. House Trading
No House trades found for PAVM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.